Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.


Speaker 3: (00:32)
 Would you tell us a little bit about yourself and your history with this testing?

 

Speaker 3: (01:25)
 Would you tell us a little more about this assay?

 

Speaker 3: (04:57)
 Which patients should have this testing and when should it be performed? 

 

Speaker 3: (05:30)
 What alternative tests exist and how do they compare?

 

Speaker 3: (06:28)
 How are the results used in patient care?

What is Answers from the Lab?

A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.